4.1 Article

Symptoms and treatment of bipolar patients in Sweden

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2011.653377

关键词

Bipolar disorder; symptoms; rating scale; prediction

资金

  1. Stockholm County Council (ALF) [20060306, 20080247]
  2. Soderstrom-Konigska Foundation
  3. Bristol-Myers Squibb
  4. Organon
  5. Pfizer
  6. Janssen-Cilag
  7. AstraZeneca
  8. Eli Lilly
  9. Sanofi-Aventis

向作者/读者索取更多资源

Objective. The objective of the study was to investigate affective symptoms and pharmacological treatment in bipolar I disorder patients, and to test whether self-rated symptoms could predict hospital admissions during a 12-month follow-up period. Methods. A total of 231 outpatients with clinical bipolar I disorder were recruited. The clinical diagnoses were reassessed by a semi-structured interview. Twenty-four patients (10%) was reclassified as bipolar disorder type II or schizoaffective disorder (bipolar type). Medication status was recorded and symptoms were assessed with the self-rating scale AS-18. Patients were prospectively followed for 12 months and hospitalizations during that time were recorded. Results. More than half (60%) rated themselves as normothymic. Mixed affective symptoms were more common than either depressive or manic/hypomanic symptoms. The admission rate during 1 year of follow-up was 13% (95% C.I.8-17%). Patients which at baseline rated themselves high in either mania or in depression had a significantly increased risk for hospitalization (OR = 3.15; 95% C. I. 1.38-7.19). Conclusions. The findings should encourage clinicians to use patient self ratings in order to identify patients with a high risk for hospitalization for targeted interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据